Paion Overview

  • Founded
  • 2000
  • Status
  • Public
  • Employees
  • 43
  • Stock Symbol
  • PA8
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $2.26
  • (As of Friday Closing)

Paion General Information


Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Other Commercial Services
Stock Exchange
Primary Office
  • Martinstrasse 10-12
  • 52062 Aachen
  • Germany
+49 0241 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Paion Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.26 $2.36 $2.03 - $3.76 $159M 67.4M 138K $0.03

Paion Financials Summary

In Thousands,
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 194,224 194,224 141,634 159,677
Revenue 22,405 22,405 8,956 3,264
EBITDA 2,195 2,195 (10,308) (14,396)
Net Income 2,533 2,533 (7,854) (11,729)
Total Assets 34,623 34,623 27,906 27,824
Total Debt 33 33 4,967 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Paion Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Paion‘s full profile, request access.

Request a free trial

Paion Executive Team (7)

Name Title Board Seat Contact Info
Abdelghani Omari Chief Financial Officer & Managing Director of PAION Deutschland GmbH & UK subsidiaries
Jürgen Beck Chief Development Officer
Karin Dorrepaal Ph.D Vice Chairman-Supervisory Board
You’re viewing 3 of 7 executive team members. Get the full list »

Paion Board Members (6)

Name Representing Role Since
Alan Goodman Avlar BioVentures Member of the Supervisory Board 000 0000
Hans Tanner Ph.D Cosmo Pharmaceuticals Board Member 000 0000
Irina Antonijevic Ph.D Self Supervisory Board Member 000 0000
John Dawson Self Supervisory Board Member 000 0000
Jörg Spiekerkötter Ph.D Self Chairman of Supervisory Board 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Paion Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Paion Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Paion‘s full profile, request access.

Request a free trial

Paion Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 23-Jun-2008 000000000000000000 Drug Discovery
To view Paion’s complete acquisitions history, request access »